At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 694 enrolled
Drug / intervention
ABT-493 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection (SURVEYOR-II)
In Brief
A Phase 3 clinical trial evaluating ABT-493, ABT-530, and 2 other interventions for Chronic Hepatitis C and Hepatitis C Virus. Completed, enrolled 694 participants.
Detailed Summary
The purpose of this phase 2/3, open-label, multipart, multicenter study was to evaluate the efficacy, and safety of co-administration of ABT-493 and ABT-530 with and without ribavirin (RBV) in chronic HCV genotype 2 (GT2-), genotype 3 (GT3-), genotype 4 (GT4), genotype 5 (GT5-), or genotype 6 (GT6-) infected participants with or without cirrhosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis C, Hepatitis C Virus
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 2014
Enrollment StartSep 2014
Primary CompletionOct 2016
Study CompletionFeb 2017
TodayJul 2026
First PostedSep 17, 2014
Enrollment StartSep 19, 2014
Primary CompletionOct 25, 2016
Study CompletionFeb 23, 2017
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 11.8 years ago
Interventions
ABT-493drug
Tablet
ABT-530drug
Tablet
ribavirin (RBV)drug
Tablet
ABT-493/ABT-530drug
Tablet; ABT-493 co-formulated ABT-530